PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive…

The following two tabs change content below.
PLoS Medicine

PLoS Medicine

PLOS (The Public Library of Science) is a non profit publisher and advocacy organization on a mission to lead a transformation in research communication. From its start, PLOS has engaged in debate about science and medicine. Content from PLoS is shared via RSS through GHHub using the Creative Commons. http://www.plosmedicine.org/

by Priya Srinivasan, Xiaofang Wu, Mousumi Basu, Christopher Rossi, Anthony D. Sandler Background Adaptive immune resistance induces an immunosuppressive tumor environment that enables immune evasion. This phenomenon results in tumor escape with progression and metastasis. Programmed cell death-ligand 1 (PD-L1) expressed on tumors is thought to inhibit tumor-infiltrating lymphocytes (TILs) through programmed cell death 1 (PD1), enabling adaptive immune resistance. This study investigates the role of PD-L1 in both mouse and human neuroblastoma immunity.

Link: 

PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive…